Benzinga · Aug 31, 2026
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
RO
NASDAQ · ROIV
Roivant Sciences Ltd.
Healthcare · Biotechnology
$41.81
Down-$0.87 (-2.08%)
Updated Sep 11, 2026, 12:47 AM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 14.83B
- P/E ratio
- -38.83
- Dividend yield
- 0.00%
- 52-week range
- $13.81 – $42.50
- Volume
- 11.15M
- Avg. volume
- 8.16M
Price performance
ROIV price history
1M range · 19 trading sessions · Daily adjusted prices
ROIV closed at $41.81 after 19 trading sessions, up 15.24% for the selected period.
- Last close
- $41.81
- Period change
- +15.24%
- Period low
- $34.18
- Period high
- $41.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $41.39 | $42.275 | $41.0808 | $41.81 | 11.15M |
| Sep 8, 2026 | $39.98 | $42.50 | $38.41 | $41.48 | 24.67M |
| Sep 4, 2026 | $34.20 | $35.145 | $33.88 | $34.93 | 5.24M |
| Sep 3, 2026 | $34.35 | $34.43 | $33.67 | $34.41 | 6.86M |
| Sep 2, 2026 | $34.64 | $35.0365 | $33.43 | $34.18 | 6.2M |
| Sep 1, 2026 | $34.64 | $34.95 | $34.26 | $34.52 | 6.91M |
| Aug 31, 2026 | $34.83 | $35.34 | $34.015 | $34.64 | 39.47M |
| Aug 28, 2026 | $37.01 | $37.13 | $34.685 | $34.71 | 8.76M |
| Aug 27, 2026 | $36.845 | $37.81 | $36.50 | $37.58 | 4.92M |
| Aug 26, 2026 | $36.925 | $36.93 | $36.32 | $36.75 | 5.26M |
| Aug 25, 2026 | $36.82 | $37.29 | $36.31 | $36.47 | 4.48M |
| Aug 24, 2026 | $36.22 | $36.569 | $35.705 | $36.36 | 5.12M |
| Aug 21, 2026 | $37.03 | $37.18 | $36.225 | $36.30 | 6.19M |
| Aug 20, 2026 | $36.91 | $37.55 | $36.68 | $36.84 | 3.13M |
| Aug 19, 2026 | $37.83 | $37.97 | $36.75 | $37.40 | 5.81M |
| Aug 18, 2026 | $35.91 | $37.46 | $35.86 | $37.37 | 6.41M |
| Aug 17, 2026 | $36.22 | $37.19 | $35.65 | $36.24 | 7.73M |
| Aug 14, 2026 | $36.135 | $36.49 | $35.87 | $36.20 | 4.53M |
| Aug 13, 2026 | $36.70 | $36.70 | $35.78 | $36.28 | 6.03M |
Latest ROIV news
The latest Smart Investors Daily articles mentioning ROIV.
Stock researchCompany · Overview
ROIV research
Overview
Company profile and research snapshot.
Company profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | TD Cowen | Buy | — |
| Sep 9, 2026 | Guggenheim | Buy | — |
| Sep 8, 2026 | Jefferies | Buy | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 28, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 30, 2026
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis - Slideshow
2026-08-30. The following slide deck was published by Roivant Sciences Ltd.
Yahoo · Aug 28, 2026
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch. Matt Gline, Roivant’s CEO, called the approval a significant milestone for patients w
SeekingAlpha · Aug 28, 2026
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis August 28, 2026 8:00 AM EDTCompany...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
